INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas

Panelists discuss how the INDIGO trial results and vorasidenib's approval could shift treatment paradigms for IDH-mutant low-grade gliomas, weighing various clinical, molecular, and patient-specific factors when considering the integration of this novel targeted therapy into individualized treatment plans.

EP: 1.Real-World Clinical Practice: Challenges With Glioma Management

EP: 2.Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas

EP: 3.CATNON Trial: Concurrent Versus Adjuvant Temozolomide in Treating WHO Grade 3 Astrocytomas Without 1p/19q Codeletion

EP: 4.IDH Inhibitors in the Treatment of Low-Grade Gliomas

Now Viewing

EP: 5.INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas

EP: 6.Closing Thoughts and Unmet Needs in Glioma Treatment

• How might the results of the INDIGO trial and the approval of vorasidenib influence treatment decisions for IDH-mutant low-grade gliomas?
• What factors would you consider when evaluating these new treatment options for patients?

Recent Videos